Dr. Roch Doliveux


Dr Roch Doliveux

Dr. Roch Doliveux was appointed to the Board as Non-Executive Chair in June 2020. Dr Doliveux was appointed interim CEO from January 2022, following John Dawson’s retirement, until March 2023 when Oxford Biomedica welcomed Dr Frank Mathias as the Chief Executive Officer. Dr. Doliveux is currently Chair of the Board of Directors at Pierre Fabre S.A. and Vice Chair of Pierre Fabre Participations. He was previously the Chief Executive Officer of UCB S.A. for ten years during which time he transformed the company from a diversified chemical group into a global biopharmaceutical leader. He was a member of the Board of UCB S.A. from 2002–2015 and from 2017–2021. In addition, Dr. Doliveux was a member of the Board of Stryker from 2010–2020 and Chair of the Compensation Committee from 2016–2020. He also chaired the Board of Vlerick Business School from 2013–2017, the Board of IMI, the largest healthcare public-private partnership in the world from 2012–2015 and GLG Institute from 2016–2022. Prior to this, Dr. Doliveux worked at Schering-Plough International, Inc. from 1990–2003 and at Ciba-Geigy AG (now Novartis) from 1982-1990. Dr. Doliveux is a Veterinary Surgeon by training and has an MBA from INSEAD.

Committee Membership

  • Nomination committee (Chair)
  • Remuneration Committee (Dr. Doliveux did not serve as a member of the Remuneration Committee whilst he served as interim Chief Executive Officer)

Relevant Skills

  • Corporate strategy
  • Corporate governance
  • Investor relations